|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2006-4-3
|
|
pubmed:abstractText |
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid and analogs were designed and synthesized as highly potent and selective CYP26 inhibitors, serving as retinoic acid metabolic blocking agents (RAMBAs), with demonstrated in vivo efficacy to increase the half-life of exogenous atRA.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BeckPatriciaP,
pubmed-author:BhagwatShripadS,
pubmed-author:BijoyPanickerP,
pubmed-author:BittnerMarkM,
pubmed-author:CastelhanoArlindo LAL,
pubmed-author:CesarioCaraC,
pubmed-author:CookeAndrewA,
pubmed-author:EmersonDavidD,
pubmed-author:FischettiGiaG,
pubmed-author:GibsonNeil WNW,
pubmed-author:KanJulie L CJL,
pubmed-author:KeaneDavidD,
pubmed-author:LazarescuVioricaV,
pubmed-author:MulvihillMark JMJ,
pubmed-author:NigroAnthonyA,
pubmed-author:NillsonChristyC,
pubmed-author:O'ConnorMatthewM,
pubmed-author:RussoSuzanneS,
pubmed-author:SmithVanessaV,
pubmed-author:SrebernakMaryM,
pubmed-author:SunFeng-LeiFL,
pubmed-author:VrkljanMichaelM,
pubmed-author:WinskiShannonS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2729-33
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
|
|
pubmed:affiliation |
OSI Pharmaceuticals, Inc., 1 Bioscience Park Drive, Farmingdale, NY 11735, USA. mmulvihill@osip.com
|
|
pubmed:publicationType |
Journal Article
|
